Hepatocellular carcinoma (HCC) is a cancer with a high mortality rate due to the fact that the diagnosis usually occurs at anadvanced stage. Even in case of curative surgical treatment, recurrence is common. Sorafenib and regorafenib are the only therapeutic agents that have been demonstrated to be effective in advanced HCC, thus novel curative approaches are urgently needed. Recent studies focus on the role of immune system in HCC. In fact, the unique immune response in the liver favors tolerance, which can represent a real challenge for conventional immunotherapy in these patients. Spontaneous immune responses against tumor antigens have been detected, and new immune therapies are under investigation: dendritic cell vaccination, immune-modulator strategy, and immune checkpoint inhibition. In recent years different clinical trials examining the use of immunotherapy to treat HCC have been conducted with initial promising results. This review article will summarize the literature data concerning the potential immunotherapeutic approaches in HCC patients.

Immunotherapeutic approaches for hepatocellular carcinoma / Longo, Vito; Gnoni, Antonio; Gardini, Andrea Casadei; Pisconti, Salvatore; Licchetta, Antonella; Scartozzi, Mario; Memeo, Riccardo; Palmieri, Vincenzo Ostilio; Aprile, Giuseppe; Santini, Daniele; Nardulli, Patrizia; Silvestris, Nicola; Brunetti, Oronzo. - In: ONCOTARGET. - ISSN 1949-2553. - 8:(2017), pp. 33897-33910. [10.18632/oncotarget.15406]

Immunotherapeutic approaches for hepatocellular carcinoma

Gnoni, Antonio;Gardini, Andrea Casadei;Scartozzi, Mario;
2017

Abstract

Hepatocellular carcinoma (HCC) is a cancer with a high mortality rate due to the fact that the diagnosis usually occurs at anadvanced stage. Even in case of curative surgical treatment, recurrence is common. Sorafenib and regorafenib are the only therapeutic agents that have been demonstrated to be effective in advanced HCC, thus novel curative approaches are urgently needed. Recent studies focus on the role of immune system in HCC. In fact, the unique immune response in the liver favors tolerance, which can represent a real challenge for conventional immunotherapy in these patients. Spontaneous immune responses against tumor antigens have been detected, and new immune therapies are under investigation: dendritic cell vaccination, immune-modulator strategy, and immune checkpoint inhibition. In recent years different clinical trials examining the use of immunotherapy to treat HCC have been conducted with initial promising results. This review article will summarize the literature data concerning the potential immunotherapeutic approaches in HCC patients.
8
33897
33910
Immunotherapeutic approaches for hepatocellular carcinoma / Longo, Vito; Gnoni, Antonio; Gardini, Andrea Casadei; Pisconti, Salvatore; Licchetta, Antonella; Scartozzi, Mario; Memeo, Riccardo; Palmieri, Vincenzo Ostilio; Aprile, Giuseppe; Santini, Daniele; Nardulli, Patrizia; Silvestris, Nicola; Brunetti, Oronzo. - In: ONCOTARGET. - ISSN 1949-2553. - 8:(2017), pp. 33897-33910. [10.18632/oncotarget.15406]
Longo, Vito; Gnoni, Antonio; Gardini, Andrea Casadei; Pisconti, Salvatore; Licchetta, Antonella; Scartozzi, Mario; Memeo, Riccardo; Palmieri, Vincenzo Ostilio; Aprile, Giuseppe; Santini, Daniele; Nardulli, Patrizia; Silvestris, Nicola; Brunetti, Oronzo
File in questo prodotto:
File Dimensione Formato  
15406-227605-4-PB.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 2.08 MB
Formato Adobe PDF
2.08 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1177525
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 45
social impact